Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
XBRANE.ST - Xbrane Biopharma AB
Q4 2025 Xbrane Biopharma AB Earnings Call
Feb 20, 2026 / 08:00AM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you and welcome all of you who are listening in to our webcast in relation to, the fourth quarter report of 2025 for XBrain BioPharma. As usually, I will, go through a brief, operational update and Jane will thereafter go through the financials for the quarter and then we will have, a Q&A session where. You can either ask questions via audio or via the chat.
So we're going to start off with talking a little bit about umimlucid, our biosimilar to, the eye drug Lucentis, which we have co-developed together with Stada, and Sara is commercializing across, Europe and select countries in the Middle East.
It's a quite straightforward setup where we are splitting the profit contribution cost production cost and
Trustpilot
